Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dr sugreev Dwivedi Anuj Dwivedi
{"title":"Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","authors":"Dr sugreev Dwivedi Anuj Dwivedi","doi":"10.47631/jsrmbs.v4i3.623","DOIUrl":null,"url":null,"abstract":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN. This manuscript reviews the current understanding of BPDCN pathophysiology, clinical presentation, and diagnostic challenges. We delve into the mechanisms of action of tagraxofusp, explore its clinical efficacy and safety profile, and discuss its role as a potential frontline and salvage therapy. Additionally, we highlight ongoing research and future directions to optimize the use of tagraxofusp in BPDCN treatment.","PeriodicalId":422270,"journal":{"name":"Journal of Scientific Research in Medical and Biological Sciences","volume":"31 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Scientific Research in Medical and Biological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47631/jsrmbs.v4i3.623","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN. This manuscript reviews the current understanding of BPDCN pathophysiology, clinical presentation, and diagnostic challenges. We delve into the mechanisms of action of tagraxofusp, explore its clinical efficacy and safety profile, and discuss its role as a potential frontline and salvage therapy. Additionally, we highlight ongoing research and future directions to optimize the use of tagraxofusp in BPDCN treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Tagraxofusp:拓展母浆细胞样树突状细胞瘤(BPDCN)的治疗视野
母浆细胞样树突状细胞肿瘤(BPDCN)是一种罕见的侵袭性血液系统恶性肿瘤,治疗方案有限。tagraxofusp是一种cd123导向的重组融合蛋白,它的开发彻底改变了BPDCN的治疗。本文回顾了目前对BPDCN病理生理、临床表现和诊断挑战的理解。我们深入研究了tagraxofusp的作用机制,探讨了其临床疗效和安全性,并讨论了其作为潜在一线和救助治疗的作用。此外,我们强调了正在进行的研究和未来的方向,以优化tagraxofusp在BPDCN治疗中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Role of Sestrin 1 in Women with Polycystic Ovary Syndrome Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Assessment of Mothers' Knowledge about Premature infants with cerebral palsy in the Maternity and Children Hospital in Diwaniyah City Evaluation of some immunological parameters for Staphylococcus xylosus infections in patients with Systemic lupus erythematosus Level of Microbial Contamination of Freshly Prepared Fufu and Retailed Fufu
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1